title: Rivaroxaban, ticagrelor, and fidaxomicin.
authors: Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, USA.
authors: Daniel A
authors: DA
authors: Hussar
authors: Amanda F
authors: AF
authors: Schartel
mesh_terms: D000241:Adenosine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000617:Aminoglycosides / Q000009:adverse effects / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D000077732:Fidaxomicin; D006801:Humans; D009025:Morpholines / Q000009:adverse effects / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D000069552:Rivaroxaban; D013876:Thiophenes / Q000009:adverse effects / Q000627:therapeutic use*; D000077486:Ticagrelor
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000925:Anticoagulants; D009025:Morpholines; D010975:Platelet Aggregation Inhibitors; D013876:Thiophenes; D000069552:Rivaroxaban; D000077486:Ticagrelor; D000241:Adenosine; D000077732:Fidaxomicin